

**PRESS RELEASE**  
**EARLY WARNING REPORT**

RICHMOND, B.C., June 12, 2015 – bioLytical Laboratories, Inc. (the “Securityholder”) announced today that pursuant to a license agreement dated June 11, 2015, it has acquired 15,000,000 common shares (the “Shares”) of Network Oncology Inc. (the “Company”), which represents approximately 18.6% of the issued and outstanding shares of the Company. Prior to the acquisition of the Shares, the Securityholder did not own or control any Shares. The Securityholder has acquired the Shares for investment purposes. At present, the Securityholder has no intention of disposing of or acquiring any further securities of the Company. The Securityholder may dispose of or acquire ownership of further securities of the Company in the future depending upon market circumstances and other factors. Such decrease or increase in ownership will depend on numerous conditions, including the price of the Shares and general market conditions. This press release is being issued pursuant to National Instrument 62-103 – *The Early Warning System and Related Take-Over Bid and Insider Reporting Issuers* which requires a report to be filed under the Company’s profile on SEDAR ([www.sedar.com](http://www.sedar.com)) containing additional information respecting the foregoing matters.

For inquiries or a copy of the related early warning report required under Canadian provincial securities legislation, a copy of which has also been filed on [www.sedar.com](http://www.sedar.com), please contact:

bioLytical Laboratories, Inc.  
1108-13351 Commerce Parkway  
Richmond, British Columbia, V6V 2X7  
Attention: Robert Mackie